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Abstract
Biallelic mutations in SLC29A3 cause histiocytosis-lymphadenopathy plus syndrome, also known as H syndrome (HS).
HS is a complex disorder, with ~ 25% of patients developing autoinflammatory complications consisting of unexplained
fevers, persistently elevated inflammatory markers, and unusual lymphadenopathies, with infiltrating CD68+, S100+, and
CD1a− histiocytes, resembling the immunophenotype found in Rosai-Dorfman disease (RDD). We investigated the
transcriptomic profiles of monocytes, non-activated (M0), classically activated (M1), and alternatively activated macro-
phages (M2) in two patients with HS, one without autoinflammatory (HS1) and one with autoinflammatory complica-
tions (HS2). RNA sequencing revealed a dysregulated transcriptomic profile in both HS patients compared to healthy
controls (HC). HS2, when compared to HS1, had several differentially expressed genes, including genes associated with
lymphocytic-histiocytic predominance (e.g. NINL) and chronic immune activation (e.g. B2M). The transcriptomic and
cytokine profiles of HS patients were comparable to patients with SAID with high levels of TNF. SERPINA1 gene
expression was found to be upregulated in all patients studied. Moreover, higher levels of IFNγ were found in the serum
of both HS patients when compared to HC. Gene ontology (GO) enrichment analysis of the DEGs in HS patients
revealed the terms “type I IFN,” “IFNγ signaling pathway,” and “immune responses” as the top 3 most significant
terms for monocytes. Gene expression analysis of lymph node biopsies from sporadic and H syndrome-associated RDD
suggests common underlying pathological process. In conclusion, monocytes and macrophages from both HS patients
showed transcriptomic profiles similar to SAIDs and also uniquely upregulated IFNγ signature. These findings may help
find better therapeutic options for this rare disorder.
Keywords H syndrome . systemic autoinflammatory disease . interferon gamma
Key Points
• Regulome analysis of monocytes and macrophage subsets in H
syndrome patients shows an autoinflammatory phenotype.
• Gene expression analysis of lymph node biopsies from sporadic and H
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Introduction
Biallelic mutations in SLC29A3, encoding the intracellular
equilibrate nucleoside transporter 3 (ENT3), cause a range of
related genetic disorders, collectively known as histiocytosis-
lymphadenopathy plus (OMM #602782) or H syndrome (HS)
[1–3]. The spectrum of clinical features associated with HS
includes dermatological (hyperpigmentat ion and
hypertrichosis) and systemic manifestations, such as
hepatosplenomegaly, hearing loss, hypogonadism, heart
anomalies, short stature, hyperglycemia (non-autoimmune
insulin-dependent diabetes melli tus (IDDM)) and
camptodactyly [2, 4]. The histiocytosis, when present, most
closely resembles Rosai-Dorfman disease (RDD), which is
characterized by infiltrating CD68+, S100+, and CD1a− histio-
cytes [5]. To date, no correlation between mutation type, or
genomic location, and severity of the phenotype has been
demonstrated [2].
Recently, HS has been described as a systemic
autoinflammatory disease (SAID), since up to 25% of HS
patients develop typical complications including unexplained
fevers, seronegative arthritis, and persistently elevated inflam-
matory markers [2, 4, 6, 7]. The term “autoinflammation”was
coined in 1999 to describe a non-infectious inflammatory
state, which was due to disturbance of the innate immune
system with monocytes, macrophages, and neutrophils being
critical cellular mediators of this process [8]. The wide range
of clinical manifestations in HS is probably due to the fact that
ENT3 plays an essential role in several biochemical reactions,
which include the regulation of nucleic acids, lysosomal ho-
meostasis, mitochondrial function, and cellular migration
[9–11]. Considering that mitochondrial dysfunction and oxi-
dative stress are closely linked with several critical innate-
immune inflammatory pathways, including NLRP3
inflammasome activation, and the fact that macrophages show
the highest expression of this transporter [9], this might ex-
plain why some patients develop SAID-like complications.
Murine studies have shown that macrophages have a crit-
ical role in the disease pathogenesis. Similar to the clinical
features observed in patients, Ent3−/−mice also develop spon-
taneous splenomegaly and lymphadenopathy early in life,
with a significantly higher number of macrophages in the
spleen but typical numbers of T and B cells [9].
Furthermore, in these mice, splenic macrophages show in-
creased M-CSFR expression with increased levels of M-CSF
in the sera of these mice [9]. While blocking M-CSF resulted
in a partial reduction of the number of splenic macrophages, it
did not change the mortality rate seen in Ent3−/− mice or
completely rescue the phenotype, indicating that other mech-
anisms must be responsible for this phenotype.
To investigate which biochemical processes and inflamma-
tory pathways are most relevant to the pathogenesis of inflam-
matory complications in HS, we performed transcriptomic
analyses in monocytes, non-activated macrophages (M0),
classically activated macrophages (M1), and alternatively ac-
tivated macrophages (M2) from two HS patients, one without
and one with inflammatory complications. We compared the
findings to a similar analysis performed in two patients with
SAID. Moreover, we compared our transcriptomic data to
other published cases of classical SAIDs. Finally, we com-
pared the transcriptomic profile of the HS patient with
autoinflammatory complications, with tissue biopsies (RDD)
obtained from sporadic cases and genetically confirmed HS
patients. This study provides the first transcriptomic insights
into the dysregulated cellular mechanisms in monocytes and
macrophages from HS patients. We show that monocytes and
macrophages share similar transcriptomic and cytokine pro-
files as SAIDs.
Methods
Patients’ Characteristics and Study Design
Patient blood samples used for this study were obtained with
ethics approval (REC 10/H1306/88, National Research Ethics
Committee Yorkshire and Humber–Leeds East), and all the
studies involving human samples from healthy control (HC)
volunteers were approved by the Health Research Authority
(REC reference 17/YH/0084). Patients were recruited from
the Department of Clinical Immunology and Allergy, St
James’s University Hospitals, Leeds, UK. Informed written
consent was obtained from all participants at the time of the
sample collection. Age- and sex-matched HC were recruited
from the St James’s University Hospitals, Leeds, UK. Details
for the tissue biopsies can be found in Supplementary Table 1.
Preparation of Human Blood and Isolation of Immune
Cells
Blood samples were collected in EDTA precoated tubes and
processed within the next 4 h. Peripheral blood mononuclear
cells (PBMCs) were isolated from whole blood using a stan-
dard density gradient centrifugation method. Blood was
mixed with an equal volume of DPBS (without Ca2+ and
Mg2+, containing 2% heat-inactivated fetal bovine serum
(FBS)) and carefully layered onto Lymphoprep (StemCell)
and centrifuged at 1100×g for 20 min without brakes. The
white buffy layer was collected and washed twice in DPBS
(2% FBS) by centrifuging at 150×g for 10min without brakes,
to remove platelets. After PBMCs were obtained, CD14+
monocytes were isolated by immunomagnetic negative selec-
tion, using the EasySep Human Monocyte Isolation Kit
(StemCell). Isolated monocytes were immediately lysed with
TRIzol or differentiated to macrophages as described in the
next sections. Table 1
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M1/M2 Macrophage Differentiation and Polarization
Isolated human monocytes were cultured in complete
RPMI medium (10% FBS, 50 U/ml penici l l in ,
50 μg/ml streptomycin and 1% L-glutamine) (Merck)
supplemented with 20 ng/mL human GM-CSF
(PeproTech) for macrophage differentiation and incubat-
ed for 6 days, adding fresh media on day 3. On day 6,
M0 macrophages were activated with 100 ng/mL human
IFN-γ (PeproTech) and 50 ng/mL LPS, for M1 macro-
phage polarization, or 20 ng/mL IL-13 (PeproTech) and
IL-4 (PeproTech), for M2 macrophage polarization, and
incubated for 24 h. Monocytes were initially seeded at a
density of 0.5 × 106 and cultured in tissue culture-treated
12 well plates.
Flow Cytometry
Characterization of the macrophages was done through flow
cytometry. On day 7, cells were washed twice with DBPS and
detached using DPBS with EDTA 10mM. Cells were washed
with DPBS and resuspended in brilliant stain buffer (BSB)
with human and mouse serum for 20 min on ice. Cells were
stained with the surface markers for M1 (CD64+, CD80+, and
CD86+) and M2 (CD64+, CD206+, and CD209+) for 30 min
on ice. Finally, cells were resuspended in BSB in FACS
collect ion tubes, and samples were run in the
CytoFLEX-LS (Beckman Coulter). All antibodies used
are listed in detail in the table of regents.
RNA Preparation and Analysis
Total RNA was obtained by using TRIzol and Phasemaker
Tubes (Thermo Fisher Scientific) according to the manufac-
turers’ protocol. RNA quality and quantity were further deter-
mined by NanoDrop spectrophotometer and with the Agilent
TapeStation (Agilent Technologies).
RNA Sequencing
Library preparation and RNA sequencing (RNA-seq) were
performed on an Illumina Novaseq and generating 150 bp
paired-ended reads (Novogene Bioinformatics Technology
Co., LTD). An average of 55.0 million raw reads were gener-
ated per sample (effective rate average 97.6% and Q30 aver-
age of 94.5%). RNA-seq raw reads were trimmed using
TrimGalore [12] to remove library adaptors sequences and
low-quality reads (QV ≤ 30). High-quality reads were mapped
to the reference genome (GRCh38/hg38) using STAR [13],
and then the Cufflinks-Cuffdiff (v2.2.1) pipeline [14] was
employed to perform transcriptome assembly, normalization,
and differential expression (DE) analyses. Monocytes and
macrophages showed an average of 89.3% uniquely mapped
reads, whereas tissue samples showed an average of 48.5%.
Processed and raw RNA-seq data have been deposited to the
NCBI Gene Expression Omnibus (GEO) database (accession
number: GSE155697). Gene-ontology (GO) enrichment anal-
ysis of the DEGs was performed using the DAVID (v6.8)
functional annotation analysis tool [15].
Table 1 Patients’ and HC
demographics Subject Age Sex Mutation
H syndrome 1 (HS1) 18 F SLC29A3
NM_018344.5:c.182G > T, p.(Gly61Val)
H syndrome 2 (HS2) 26 F SLC29A3
NM_018344.5:c.300 + 1G>A
Undefined SAID (uSAID) 55 M TNFRSF1A
c.1328G > T, p(Gly443Val)
TRAPS 31 F TNFRSF1A
c.236C > T (p.Thr79Met)
HC1 36 F N/A
HC2 45 M N/A
HC3 26 F N/A
HC4 18 F N/A
HC5 35 F N/A
HC6 36 F N/A
HC7 27 F N/A
HC8 22 M N/A
HC9 44 F N/A
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Cytokine Detection
The supernatant from cultured macrophages and patients’ se-
rum were frozen and stored at − 80 °C. TNF, IL-12, IL-6, IL-
1β, IFNγ, and IL-2 (R+D Systems Fluorokinemap) cytokines
were measured by using the multiplex Luminex analyzer
(Bio-Plex, Bio-Rad, UK). Serum was collected immediately
after the sample collection, and supernatants from macro-
phages were collected before processing the cells.
Quantification and Statistical Analysis
Flow cytometry and cytokine analysis were analyzed by mul-
tiple independent t tests, and statistical significance deter-
mined by the Holm-Sidak method. Each parameter was ana-
lyzed individually without assuming a consistent SD.
GraphPad Prism 8 software was used to do all analyses. P
values of < 0.05 were statistically significant. Nonparametric
tests were used to compare the medians between groups.
Table of Reagents





The first H syndrome patient (HS1) is an 18-year-old female
of Pakistani consanguineous descent. The patient initially pre-
sented at the age of 12 with IDDM associated with positive
anti-islet cell antibodies. Within a year of initial presentation,
the patient developed camptodactyly and fleeting pain and
swelling in other joints, including the right knee, wrist, elbow,
and temporomandibular joint. Further investigations in pedi-
atric rheumatology did not show any evidence of active in-
flammatory arthritis, and the joint symptoms settled spontane-
ously within the following 6 to 9 months. Subsequent genetic
analysis revealed a rare, previously unreported, homozygous
va r i an t in SLC29A3 (NM_018344 .5 :c .182G>T,
p.(Gly61Val)) as the likely cause of disease. The patient’s
younger sister, who, in addition to camptodactyly and
IDDM, also had short stature (9th centile) and
hypertrichosis was later found to share the same genetic
variant. HS1 has remained otherwise well, apart from
IDDM and camptodactyly, and has not developed any
inflammatory complications.
The second patient (HS2) is a 26-year-old female of
consanguineous Pakistani descent. A detailed description
of the patient’s clinical features and treatment history
has been published previously [16]. Briefly, the patient
first came to medical attention at the age of 2 years
after presenting with a self-limiting, well-delineated tel-
angiectatic rash. Over the ensuing decade, the patient
developed arthralgia, fatigue and dactylitis, and at the
age of 9, the patient was found to have RDD causing
non - t ende r submand ibu l a r l ymphadenopa t hy .
Subsequently, she was diagnosed with HS due to the
identification of a homozygous splice-site mutation in
SLC29A3 (NM_018344.5:c.300+1G>A). The patient’s
other clinical features are consistent with this diagnosis,
including short stature, IDDM, and pancreatic insuffi-
ciency. In the ensuing years, she has developed numer-
ous inflammatory complications, which continue to be
problematic, including sporadic fevers, transient synovi-
tis, persistently elevated CRP, and progressive RDD,
which now also involves her skin. She was treated with
numerous disease-modifying antirheumatic (DMARD)
medications, including biological therapies such as ri-
tuximab and tocilizumab, which have not been effective.
SAID
The first undefined SAID patient (uSAID) is a 55-year-old
male who has a life-long history of unexplained fevers asso-
ciated with flu-like symptoms lasting anywhere between a few
days to weeks. The patient’s clinical picture is complicated by
recurrent episodes of cellulitis as a result of complex trauma in
his left knee. Sequencing revealed a previously unreported
heterozygous single nucleotide variant of unknown signifi-
cance c.1328G>T, p(Gly443Val), in exon 10 of the
TNFRSF1A gene. The patient is receiving on-demand treat-
ment with prednisolone, which he infrequently takes for the
autoinflammatory complications, similar to those presented
by patients with TNF-Receptor Associated Periodic
Syndrome (TRAPS).
Fig. 1 Transcriptomic sample analysis in both monocytes and
macrophages. (a) CD14+ monocytes obtained by negative selection
were differentiated into macrophages for 6 days, and then M1
macrophage polarization was accomplished by stimulating with
100 ng/ml human IFNγ and 50 ng/ml LPS. M2 macrophage polarization
was accomplished by stimulating with 20 ng/ml IL-13 and 20 ng/ml IL-4.
M0 macrophages were cultured for 7 days. (b) Multidimensional scaling
(MDS) plot showing the global transcriptomic profile of all the HC (1–5)
and patients’ samples, where all the different cell types are shown. (c and
d) MDS plot showing the global transcriptomic profile in monocytes and
M1 of all the HC and patients’ samples. (e–g) The number of differen-
tially expressed genes (DEGs) in pairwise comparisons of the different
cell types are given, where monocytes (top) and M0 (bottom) are com-
pared to each other cell type. The Venn diagrams show shared and unique
DEGs for each cell type in (e) HC, (f) HS1, and (g) HS2 samples
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The second patient (TRAPS) is a 31-year-old female who
has been symptomatic since her early teens with episodic fe-
vers and serositis. She carries a c.236C>T (p.Thr79Met)
mutat ion in TNFRSF1A , previously described as
p.Thr50Met [17]. At present, she is treated effectively with
anakinra (synthetic IL-1 receptor antagonist).
J Clin Immunol
Transcriptomic Differences of Monocytes and
Macrophages
To study the transcriptomic profile of monocytes, M0,
M1, and M2 macrophages, we obtained CD14+ mono-
cytes from 2 HS, 2 SAID patients, and 5 HC and dif-
ferentiated the cells according to the protocol summa-
rized in Fig. 1a. To determine whether the macrophage
differentiation was successful, the global transcriptomic
differences between the different cell types, in each
group, were assessed and visualized using multidimen-
sional scaling (MDS) plots (Fig. 1b–d). Monocytes, M0,
and M1 macrophages were clearly separated, by at least
three units on the MDS plot, for each sample (Fig. 1b).
Although the M2 and M0 macrophages did not show a
distinct global transcriptomic difference by MDS, we
found this to be consistent with another published
dataset available of M2 differentiated from M0 macro-
phages [18]. Moreover, expression of the surface
markers CD80/CD86 and CD206/CD209 showed high
expression in M1 and M2 macrophages, respectively.
To further corroborate the differences between the cell
types, pairwise comparisons were made between the dif-
ferent cell types in each group (Fig. 1e–g). As shown in
the Venn diagrams, a large number of transcripts were
found to be differentially expressed in M0, M1, and
M2, when compared to monocytes; for example, HC
(n = 5) and HS1 showed 2210 and 2045 DEGs in M1
macrophages, respectively, and M1 macrophages from
patient HS2 presented 905 DEGs (Fig. 1e–g top).
When compared to M0 macrophages, the transcriptomic
differences of monocytes were more evident, with 2714
(HC), 2337 (HS1), and 1273 (HS2) DEGs (Fig. 1e–g
bottom). Similarly, when comparing to monocytes, M2
macrophages showed 344 (HC), 440 (HS1), and 128
(HS2) DEGs in each respective group (Fig. 1e–g top).
The number of DEGs was reduced in the different cell
types from the uSAID and TRAPS patients. We observed 80
and 149 unique DEGs in M2 and M1 macrophages from
uSAID patient and 102 and 93 in M2 and M1 macrophages
from the patient with TRAPS (Supplemental Fig. 1C-D). The
remaining comparisons of all the DEGs in each cell type from
each sample group are shown in Supplemental Fig. 1E-G.
Transcriptomic Profile of Two Different H Syndrome
Patients
To determine which cellular processes might be responsible
for the differences in the inflammatory phenotypes observed
between the two HS patients, we first compared the global
transcriptomic profile of cells derived from HS patients.
While heterogeneity is an important factor that influences
the transcriptomic profiles of cell subset in different
individuals [19], we still observed a clear degree of separation
in the monocytes from the two HS patients when compared to
the HC samples (Fig. 1c) and to a lesser degree in the other cell
subsets (Fig. 1d; Supplemental Fig. 1A-B).
We next conducted pairwise comparisons of the DEGs be-
tween both HS patients, as well as independently against the HC
samples, for each cell type.Monocytes fromHSpatients shared a
cluster of upregulated genes when compared to the HC controls
(Fig. 2a), and a total of 73 and 70 DEGs were shown in patients
HS1 and HS2, respectively (Supplement Table 4). The shared
upregulated DEGs in both HS patients included SERPINA1,
TNFAIP6, and SLC39A8 (Fig. 2b). When monocytes from pa-
tients HS1 and HS2 were compared, we found 77 DEGs with
several HLA genes being overexpressed in patient HS2, as well
as B2M, which encodes β2-Microglobulin, a component of
MHC class I molecules (Fig. 2b).
When comparing transcriptomic profiles ofM0macrophages,
patient HS1 showed a profile resembling the HC samples rather
than HS2 (Fig. 2c). The number of DEGs in M0 macrophages
was 58 in HS1 and 154 in HS2, when compared to HC samples.
Similarly, when the two HS patients were compared to each
other, we observed 71 DEGs, including B2M and HLA genes,
upregulated and lysosomal-associated membrane protein 3
(LAMP3) downregulated in patient HS2 (Fig. 2d).
A cluster of overexpressed genes was found in M1 macro-
phages from the two HS patients when compared to HC samples
(Fig. 2e). In M1 macrophages, several inflammatory genes such
as IFN-responsive genes, TNF, IL-1α and IL-1β were upregu-
lated in both HS patients (Fig. 2f). In M2 macrophages, we still
observed a different transcriptomic profile in the two HS patients
(Fig. 2g). A total of 653 and 422 DEGs were found in M2
macrophages from HS1 and HS2 patients when compared to
HC samples, several of the genes shown in Fig. 2h. The full list
of DEGs can be found in Supplemental Table 4.
H Syndrome as an Autoinflammatory Disease
To classify genes with the most significant differences in the
patients, the top 15 upregulated and 15 downregulated DEGs
(ranked by fold change) in each cell type were identified
(Fig. 3a–d). Additionally, to determine whether the gene ex-
pression profile of H syndrome patients resembles that
of patients with SAID, we included the data from two
SAID patients, which were also characterized by
transcriptomic profiling alongside the HS patients (Fig.
1b–d; Supplemental Fig. 1A-D).
The SERPINA1 gene, which encodes alpha1-
antitrypsin (AAT), was found to be the most or second
most upregulated gene in all cell types from both HS
and SAID patients compared to HC (Fig. 3a–d). M0
macrophages from HS and SAID patients exhibited a
comparable gene expression profile with similar levels
of SERPINA1, LOC105376781, F13A1, CD1A, ASGR2,
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CCL17, MMP12, and CLDN1 when compared to con-
trols (Fig. 3b). Moreover, in M1 macrophages, 12 genes
were found to be similarly expressed among the two HS
and SAID patients, with SERPINA1 being the top up-
regulated gene (Fig. 3c).
To further elucidate the unique DEGs, in monocytes
and macrophages, which may be responsible for the
autoinflammatory phenotype presented by HS2 patient,
we compared the transcriptomic profile HS2 against
HS1 and ranked the DEGs by fold change (Fig. 3e–h).
Corroborating our previous findings, SERPINA1 was not
found in the list of DEGs, when comparing the two HS
patients, suggesting that this gene is a shared marker in
SAIDs. Remarkably, B2M was the top upregulated gene
in all cell types from HS2 patient (Fig. 3e–h). M1 mac-
rophages from HS2 patient showed increased levels of
NINL and SNHG5, which have been associated with
Hodgk in ’ s lymphoma lymphocy t i c -h i s t i o cy t i c
predominance (Fig. 3g). In the M0 macrophages from
the HS2 patient, we observed downregulation of
LAMP3, which is related to lysosomal function.
We next performed gene ontology (GO) analysis of the
DEGs in HS and SAIDs, when compared to HC.
Macrophages from HS patients revealed a significant enrich-
ment of GO terms related to immune responses, IFN signal-
ing, and MHC class I (Fig. 4) (Supplemental Fig. 2A). For
instance, the biological process (BP) GO term “Interferon-
gamma-mediated signaling pathway” (GO:0060333)
displayed a fold enrichment of 27.4 in monocytes, 14.1 in
M0, 15.2 in M1, and 5.6 in M2, in both HS patients with
FDR < 0.001 (Supplemental Table 5). Several of the top 15
GO terms in HS patients were also shown in uSAID and
TRAPS patients (Fig. 4). For example, the GO term
“Immune response” (GO:0006955) was in the top 4 terms
from all cell types in HS and SAID patients (Fig. 4)
(Supplemental Fig . 2A). Although the GO term
Fig. 2 Different transcriptomic profile in HS patients. Pairwise
differential expression comparison between HC (1–5) and patients’
samples, as well as between the HS1 and HS2 patients in all different
cell types. (a, c, e, and g) Heatmaps show only the DEGs (q < 0.05)
between the 3 different groups, HC, HS1, and HS2, monocytes, M0,
M1, and M2, accordingly. The expression was standardized, and the
color shading scale represents Log2(FPKM) values. Genes (rows) were
hierarchically clustered (Euclidean). (b, d, f, and h) Volcano plots show-
ing the DEGs in Log2 (fold change) and p value for the comparisons of
HC vs HS1 (left), HC vs HS2 (middle), and HS1 vs HS2 (right) in
monocytes, M0, M1, and M2, accordingly. Differentially expressed
genes in volcano plots (FC ≥ 1, p < 0.05 with FDR) are depicted in red.
The purple boxes show a cluster of genes similarly expressed in the two
HS patients
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“Inflammatory response” (GO:0006954) was significantly
enriched in all the patients, this term was more enriched in
M2 macrophages from all the patients, fold enrichment of 3.0
(HS) and 2.5 (uSAID and TRAPS) with a FDR < 0.0001 (Fig.
4d–e) (Supplemental Table 5).
Furthermore, to compare gene expression profiles between
HS patients and other defined SAID patients, we obtained and
analyzed published transcriptome data from individuals diag-
nosed with either neonatal onset multisystem inflammatory
disease (NOMID), NLRC4 macrophage activation syndrome
(NLRC4-MAS) or A20 haploinsufficiency (due to mutation
of TNFAIP3) [20, 21] (GSE57253 and GSE95078). DEGs
were identified for each disorder, compared to the matched
controls present in the same dataset and then compared to
the DEGs identified in HS patients (Fig. 5). Consistent with
our previous findings, the upregulation of SERPINA1 was
found to be shared in all SAID and HS patients’ samples
(Fig. 5a–d). Moreover, the inflammatory markers CXCL8,
TNFAIP6, and IL-1βwere also shared between the conditions
(Fig. 5a–d).
GO analysis of shared DEGs between HS and SAID
patients revealed significant enrichment of GO terms,
such as “ type I interferon signal ing pathway”
(GO:0060337), “MHC class I protein complex”
(GO:0042612) and “Immune response” (GO:0006955)
(Fig. 5e–h) (Supplementary Table 3). Altogether, these
data suggest a similar transcriptomic profile in HS and
SAID patients.
Sporadic and H Syndrome-Associated RDD
To determine if similar biological processes are involved in
the pathogenesis of RDD related to H syndrome and in id-
iopathic cases, we compared transcriptomic profiles of tis-
sue lymph node biopsies obtained from five sporadic cases
of RDD and the HS2 patient. Pairwise comparison of
Fig. 3 Signature DEGs in monocytes and macrophages from HS and
SAID patients. Pairwise comparison of HS1, HS2, uSAID, and TRAPS
patients vs HC (1–5) samples, in monocytes, M0,M1, andM2. (a–d) The
top 15 upregulated and 15 downregulated DEGs, in each cell type, are
shown in Log2 (fold change) based on the expression profile of the HS
patients and matching the TRAPS patients to those DEGs. (e–h) Pairwise
comparison of HS1 vs HS2, in monocytes, M0, M1, and M2. The top 10




biopsies from the five sporadic RDD cases against the HS2
failed to detect any DEGs suggesting that irrespective of the
cause, there is a common pathological mechanism under-
pinning the development of RDD. To identify signaling
J Clin Immunol
Fig. 4 GO-based gene enrichment analyses on DEGs fromHS and SAID
patients. (a–e) Gene ontology (GO) enrichment analysis of all the DEGs
in the HS and SAID patients, when compared to the HC (1–5) samples for
each different cell type. The GO annotations correspond to the three
major categories: biological process (BP), cellular compartment (CC),
and molecular function (MF). The top 15 most significant GO terms
(p < 0.01) are shown in descending order. Enrichment for GO terms
was calculated using DAVID bioinformatics web source tools. The full
list with all the terms can be found in Supplementary Table 2
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pathways that might be associated with the pathogenesis of
RDD, we filtered all the genes with fold change less than
two and greater than − 2 and took the top 3000 genes with
the highest expression. Panther pathway analysis revealed
27 s i gn i f i c an t l y en r i ch ed pa thway s i n c l ud i ng
“Inflammation mediated by chemokine and cytokine signal-
ing pathway,” “JAK/STAT signaling pathway,” and “p38
MAPK pathway” (please see supplementary Tables 7 and 8
for full details).
Dysregulated Cytokine Profile in HS and SAID Patients
Cellular plasticity confers macrophages the capacity to elicit
different immune responses, pro-inflammatory (M1), or anti-
inflammatory (M2), according to the environmental circum-
stances [22]. Abnormal proportions of M1 and M2 macro-
phages have also been reported in several immune disorders
and are associated with disease progression [23]. We evaluat-
ed macrophage polarization in HS, uSAID, and TRAPS
Fig. 5 Shared DEGs and GO-based enrichment analyses in HS and
SAIDs patients. (a–d) The number of DEGs in monocytes and M1 mac-
rophages fromHS1 (left) and HS2 (right) patients, NOMIDActive (a–b),
and NLRC4-MAS (c–d). The Venn diagrams show shared and unique
DEGs for each group, when compared with their respective controls. The
box on the right hand of each Venn diagram shows the shared DEGs in
the groups. (e–h) List of GO enrichment terms in HS and SAIDs patients.
DEGs were identified for NOMID active (active disease), NOMID inac-
tive (after treatment), NLRC4-MAS, A20 stimulated (stimulated with
TNF) and A20 unstimulated compared to the matched controls present
in the same dataset and then compared to the DEGs identified in HS
patients for each cell subtype. The top 5 terms for each HS patient are
shown. GO terms were considered significant if p < 0.01. Further details




patients, where macrophages were classified as M1 (CD64+,
CD80+, and CD86+) or M2 (CD64+, CD206+, and CD209+)
according to their surface marker expression (Fig. 6). Prior to
initiating differentiation, the TRAPS patient showed an in-
creased number of M1 macrophages (27.3%); in contrast,
the proportion ofM2macrophages was significantly increased
in the uSAID, TRAPS, and HS1 patients compared to HC
(Fig. 6a). Although proportionally no differences were ob-
served in CD64 expression, the CD64 mean fluorescent inten-
sity (MFI) was raised in all patients (Fig. 6a–b). When macro-
phages were activated, as described in Fig. 1a, HS patients
showed a decrease in the proportion ofM1macrophages, which
was more pronounced in HS2, and the proportion of M2 was
significantly increased in the uSAID, TRAPS, and HS1
patients (Fig. 6c). CD80 MFI was slightly decreased in
the two HS patients, while CD209 MFI was increased
considerably in the two SAID and HS1 patients (Fig.
6d). The M1 and M2 gating strategy can be found in
Supplemental Fig. 3. Cytokine profiles of patients pre-
sented some anomalies, showing high TNF in M0 macro-
phages from the TRAPS patient and significantly in-
creased levels of TNF in M1 macrophages from all pa-
tients (Fig. 6e–f). Although M2 macrophages from the
uSAID, TRAPS, and HS1 patients presented odd polari-
zation ratios, no significant differences were observed in
their cytokine levels (Fig. 6g). Moreover, increased serum
Fig. 6 Dysregulated macrophage
phenotype and cytokine profile in
HS and SAID patients. M0
macrophages, polarized M1 or
M2 macrophages were analyzed
by flow cytometry; also, the
cytokine profile of the
macrophages was assessed using
Luminex assay. (a and b)
Represent M0 non-activated
macrophages, where (a) show the
percentage of macrophages
(CD64+), M1 (CD64+, CD80+,
CD86+), and M2 (CD64+,
CD206+, CD209+) and (b) show
the MFI of individual markers on
each sample. (c and d) Represent
activated macrophages, where (c)
show the percentage of macro-
phages (CD64+), M1 (CD64+,
CD80+, CD86+), and M2
(CD64+, CD206+, CD209+) and
(d) show the MFI of individual
markers on each sample. (e–g)
Show the TNF, IL-12, IL-6, and
IL1β cytokine levels of the M0,
M1, and M2 macrophages on
each sample. (h) Show the TNF,
IFNγ, IL-6, and IL-2 cytokine
levels on the serum of the two HS
patients. Each symbol represents
a unique individual sample for
each of the patients and HC (1–9).
In the patient samples, the two
HS1 symbols represent indepen-
dent experiments, in two different
samples from the same subject.
Statistical significance deter-
mined using the Holm-Sidak
method; *p < 0.05, **p < 0.01,
***p < 0.001
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levels of IFNγ, TNF, IL-6, and IL-2 were shown by HS2
patient, consistent with the patient’s inflammatory clinical
features (Fig. 6h). Interestingly, both HS patients showed
increased levels of IFNγ and IL-2 (Fig. 6h).
Discussion
Systemic inflammation and development of RDD are common,
yet unexplained, features in HS patients. Both remain difficult
complications to manage since there are no standards of consis-
tently effective treatment approaches. Our study was focused on
investigating the potential role of monocytes andmacrophages in
this disease setting. Using the transcriptional approach, we pro-
vide additional data related to differentiation of monocytes into
M0, M1, and M2 macrophages under ex vivo experimental con-
dition. More importantly, this study offers new insights into pos-
sible mechanisms leading to autoinflammatory phenotype and
RDD associated with H syndrome.
When we compared HS patients with and without inflam-
matory complications, there were some apparent differences
at the transcriptomic level between HS1 and HS2, demonstrat-
ed by several DEGs, such as ADAM19, CCL17, CCL19,
CXCL5, IL32,MEG3, MMP12, and NINL. Collectively these
genes can control the cell migration in response to inflamma-
tory stimuli [24, 25] and induce an inflammatory response
[26–28]. All of these actions may account for the development
of the autoinflammatory phenotype and RDD. Intriguingly,
B2M was the top transcript upregulated in all cell subtypes
from patient HS2. B2M is usually expressed by all cells in
the human body, where the encoded protein forms complexes
with HLAmolecules [29]. Typically, increased levels of B2M
are associated with increased cell turnover, as seen in lympho-
proliferative conditions and chronic inflammation [30, 31]. In
these disease states, high levels of B2M are associated with
poor prognosis [31, 32], development of kidney failure [33]
and secondary amyloidosis [34, 35]. B2M has not been rou-
tinely measured in patients with HS, so the risk of such com-
plication in this patient group is unknown.
HS and SAID patients showed an overall similar
transcriptomic and cytokine profile, with several GO terms
enriched in both diseases. Transcriptomic analyses from HS
and SAIDs from different datasets revealed overexpression of
SERPINA1, which was shared in all cell subtypes. This find-
ing might indicate a normal biological response towards an
exaggerated inflammation, as ATT is induced upon inflam-
mation and can modulate inflammation by inhibiting IL-8 and
TNF [36–39]. This is consistent with our cytokine data, as we
observed significantly higher levels of TNF in M1 macro-
phages from all patients. Moreover, H syndrome patients pre-
sented increased serum levels of IFNγ and GO enrichment of
IFNγ-mediated signaling pathways. This finding may help to
explain the abnormal activation of histiocytes in this condition
and the increased levels of HLA genes, as IFNγ is known to
induce HLA-I and HLA-II and inflammatory cytokines
[40–42].
We also noted that the type I IFN pathway was enriched in
both HS and SAID. Enhanced type I IFN signaling is typically
associated with a group of autoinflammatory disorders termed
type I interferonopathies [43–46]. However, it has recently been
argued that the purely cytokine-/pathway-based approach to-
wards classification and understanding of the pathogenesis of
autoinflammatory disorders is probably an oversimplification
[43–46]. There is likely to be an overlap between the biological
processes which play a part in the pathogenesis of these disor-
ders, and this might depend on the type of cell which has been
studied and the stage of disease evolution.
When we compared transcriptomic profiles of tissue biop-
sies fromHS2 and patients with sporadic forms of RDD, there
were no apparent differences to report. This suggests that ir-
respective of the initial trigger for the development of RDD,
there are common immunopathological abnormalities that
drive this process.
Based on the transcriptomic and cytokine data, there
are several potential treatment targets to consider. IFNγ
has an essential effect on macrophage activation and
clearly a pathogenic role in MAS considering that
Emapalumab, which is an anti-IFNγ monoclonal anti-
body, has been recently approved for the treatment of
hemophagocy t i c lymphoh i s t i ocy tos i s [47–49] .
Furthermore, IFNγ has a role in MAPK activation [42],
a pathway that has been successfully being targeted using
MEK inhibitors, which have been shown to be efficacious
in patients with histiocytic neoplasms [50].
In addition to IFNγ, we also found IL-1β, a prototypic pro-
inflammatory cytokine associated with SAID, to be to be up-
regulated in HS patients. This was found in the M1 macro-
phages of both HS patients at not only the transcriptomic level
but also at protein level. However, the role of IL-1β in the
pathogenesis of autoinflammatory complications is probably
complex. Although only HS2 patient presented with
autoinflammatory complications, our findings suggest that
low-grade chronic inflammation is a persistent feature in these
patients and that other factors play a role in exacerbating this
state leading it to become overtly pathogenic over time.
IL-2 is a pleiotropic cytokine which has been recog-
nized for its role in the regulation and proliferation of
effector T cells and regulatory T cells (Treg) [51, 52].
Studies have shown that low doses of IL-2 promote
Treg development leading to amelioration of some auto-
immune disorders [51, 52]. Nevertheless, it has been
shown that systemic IL-2 administration can also lead to
a cytokine storm and activate mononuclear phagocytes
into mature antigen presenting cells [53]. In other studies,
it was shown that after activation with IL-2, a small subset
of innate lymphoid cells, named ILC2, increase their IL-5
J Clin Immunol
production leading to activation of M2 macrophages [54,
55]. Interestingly, we found that IL-2 levels were in-
creased in the serum of both H syndrome patients with
higher proportions of M2 in HS1. Certainly, this IL-2
imbalance can potentially disturb macrophage activation,
and low doses of IL-2 inhibitors may be efficacious in
controlling sporadic inflammation.
However, the transcriptomic and cytokine data are not al-
ways easy to interpret and translate into successful treatment
strategies. For example, although TRAPS is associated with
elevated TNF levels, targeting IL-1beta has been far more
effective and safer strategy than selectively targeting the
TNF [56, 57]. Similarly, despite our data showing that type I
IFN and JAK/STAT pathways are implicated in inflammatory
and RDD pathogenesis, pegylated IFN has been used success-
fully to treat selected cases [58].
There are several limitations to this study. They include the
limited number of patients who were included and type of the
cells that we studied. Both HS and genetically defined SAIDs
remain rare conditions, and therefore it is not always possible
to exactly match patients according to age, sex, and previous
treatments. Although we included monocytes into our study,
we did not analyze distinct subpopulations, such as classical
(CD14++, CD16−), intermediate (CD14++, CD16+), and non-
classical (CD14+, CD16+) monocytes, which are all capable of
distinctive cytokine production and have different roles in the
pathogenesis of inflammatory responses [59–61]. This analy-
sis should be included in future studies since the non-classical
monocyte subpopulation was previously recognized to be in-
creased in one patient diagnosed with H syndrome who pre-
sented with a combination of an autoinflammatory condition
and immunodeficiency [62].
In summary, we provide a novel dataset which can help to
further study monocytes and macrophages in HS and SAID
patients and distinguish several DEGs and GO enrich path-
ways that are shared in these conditions. Altogether, we show
that HS resembles an autoinflammatory condition with similar
transcriptomic and cytokine landscape with the one observed
in SAIDs.
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